MX2010005057A - Metodos y composiciones para uso de diagnostico en pacientes de cancer. - Google Patents

Metodos y composiciones para uso de diagnostico en pacientes de cancer.

Info

Publication number
MX2010005057A
MX2010005057A MX2010005057A MX2010005057A MX2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A
Authority
MX
Mexico
Prior art keywords
methods
compositions
cancer patients
diagnostic use
cancer
Prior art date
Application number
MX2010005057A
Other languages
English (en)
Spanish (es)
Inventor
Thomas D Wu
Daniel S Chen
Couter Jennifer Le
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2010005057A publication Critical patent/MX2010005057A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2010005057A 2007-11-09 2008-11-05 Metodos y composiciones para uso de diagnostico en pacientes de cancer. MX2010005057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98688407P 2007-11-09 2007-11-09
PCT/US2008/082456 WO2009061800A2 (en) 2007-11-09 2008-11-05 Methods and compositions for diagnostic use in cancer patients

Publications (1)

Publication Number Publication Date
MX2010005057A true MX2010005057A (es) 2010-05-19

Family

ID=40342593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005057A MX2010005057A (es) 2007-11-09 2008-11-05 Metodos y composiciones para uso de diagnostico en pacientes de cancer.

Country Status (13)

Country Link
US (2) US20090123930A1 (OSRAM)
EP (1) EP2222874A2 (OSRAM)
JP (1) JP2011502513A (OSRAM)
KR (1) KR20100095571A (OSRAM)
CN (1) CN101910416A (OSRAM)
AU (1) AU2008324782A1 (OSRAM)
BR (1) BRPI0817158A2 (OSRAM)
CA (1) CA2703258A1 (OSRAM)
IL (1) IL205246A0 (OSRAM)
MX (1) MX2010005057A (OSRAM)
RU (1) RU2010123381A (OSRAM)
WO (1) WO2009061800A2 (OSRAM)
ZA (1) ZA201002808B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201510152RA (en) * 2009-07-13 2016-01-28 Genentech Inc Diagnostic methods and compositions for treatment of cancer
MX2012002909A (es) * 2009-09-17 2012-04-19 Hoffmann La Roche Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
CN103109189A (zh) * 2010-07-19 2013-05-15 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
EP2596359A1 (en) * 2010-07-19 2013-05-29 F.Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG10201604497UA (en) * 2011-06-02 2016-07-28 Almac Diagnostics Ltd Molecular Diagnostic Test For Cancer
AU2013207778B2 (en) * 2012-01-13 2017-10-12 Genentech, Inc. Biological markers for identifying patients for treatment with VEGF antagonists
CN104364655A (zh) * 2012-06-26 2015-02-18 霍夫曼-拉罗奇有限公司 贝伐单抗组合疗法用于治疗乳腺癌的血浆生物标志物
CA2893033A1 (en) * 2012-12-03 2014-06-12 Almac Diagnostics Limited Molecular diagnostic test for cancer
WO2015050500A1 (en) 2013-09-17 2015-04-09 Agency For Science, Technology And Research Multigene assay for prognosis of renal cancer
GB201409479D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
EP3230498B1 (en) * 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
KR101903522B1 (ko) * 2015-11-25 2018-11-23 한국전자통신연구원 다차원 건강데이터에 대한 유사사례 검색 방법 및 그 장치
US20250155442A1 (en) * 2023-11-09 2025-05-15 Sun Jet Biotechnology Inc. Apolipoprotein a-ii biomarkers for detecting and monitoring cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
US8691506B2 (en) * 2005-04-13 2014-04-08 Oncotest Gmbh Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
WO2007123722A2 (en) * 2006-03-31 2007-11-01 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Also Published As

Publication number Publication date
AU2008324782A1 (en) 2009-05-14
RU2010123381A (ru) 2011-12-20
US20090123930A1 (en) 2009-05-14
KR20100095571A (ko) 2010-08-31
EP2222874A2 (en) 2010-09-01
WO2009061800A3 (en) 2009-07-16
JP2011502513A (ja) 2011-01-27
CA2703258A1 (en) 2009-05-14
ZA201002808B (en) 2011-07-27
CN101910416A (zh) 2010-12-08
US20110151468A1 (en) 2011-06-23
IL205246A0 (en) 2010-12-30
WO2009061800A2 (en) 2009-05-14
BRPI0817158A2 (pt) 2015-04-14

Similar Documents

Publication Publication Date Title
WO2009061800A3 (en) Methods and compositions for diagnostic use in cancer patients
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
PT3130923T (pt) Métodos terapêuticos relacionados com células estaminais
MX2012002909A (es) Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
IL190733A0 (en) Methods and compositions for use in treatment of patients with autoantibody positive diseases
GB0708761D0 (en) Improvements in and relating to medical instruments
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
MY160041A (en) Compositions and methods for treating parasitic infections
IL206079A0 (en) Microrna expression profiling and targeting in peripheral blood in lung cancer
GB0920703D0 (en) Compositions containing satiogens and methods of use
PH12012501067A1 (en) Combination therapy for treating cancer and diagnostic assays for use therein
IL206748A (en) Molecular test for @cancer @ breast cancer @
PT2282758T (pt) Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
MX2009010066A (es) Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
EP2614375A4 (en) COMBINATION METHOD FOR CANCER DIAGNOSIS
NZ584606A (en) An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO2010054377A3 (en) Fully human antibodies against n-cadherin
MX2013003599A (es) Interferon-beta para uso como monoterapia o en combinacion con otras terapias de cancer.
PT2320900T (pt) Utilização de opioides ou miméticos de opioides para o tratamento de pacientes com cancros resistentes
IL217209A0 (en) Novel antibodies and their uses in therapeutic and diagnostic methods
GB2465907A (en) VHZ for diagnosis and treatment of cancer
PL2291657T3 (pl) Stężenie heterotrimerów blys/april w surowicy oraz zastosowanie w sposobach diagnostycznych
UA95956C2 (uk) Набір для визначення mage-а3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal